0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Lab Reports |

Nanoparticle Strategy Enhances Delivery of Cancer Drugs

Tracy Hampton, PhD
JAMA. 2016;315(17):1825. doi:10.1001/jama.2016.4946.
Text Size: A A A
Published online

Extract

A newly developed injectable nanoparticle generator (iNPG) has effectively delivered chemotherapy to lung metastases in mouse models of triple-negative breast cancer, which lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression (Xu R et al. Nat Biotechnol. doi:10.1038/nbt.3506 [published online March 14, 2016]).

The system components include a nanoporous biodegradable silicon material and a polymer, poly(l-glutamic acid), that is connected to doxorubicin, a chemotherapeutic agent, via a pH-sensitive cleavable linker (pDox). When intravenously injected into mice, the iNPG-pDox naturally accumulated at sites of metastases due to blood vessel leakiness surrounding tumors. The silicon material then degraded, releasing pDox, which spontaneously formed nanometer-sized particles that were taken up by individual cancer cells. Once inside the cancer cells, the acidic pH close to the nucleus caused the links between doxorubicin molecules and the polymer to break, releasing doxorubicin at a cellular location devoid of drug efflux pumps. High concentrations of doxorubicin were maintained for more than 1 week after administration.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

364 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();